All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

tovorafenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors	5819	1096708-71-2

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: tovorafenib ojemda DAY101 TAK-580 MLN2480

Tovorafenib is a Type II RAF kinase inhibitor of mutant BRAF V600E, wild-type BRAF, and wild-type CRAF kinases. Tovorafenib exhibited antitumor activity in cultured cells and xenograft tumor models harboring BRAF V600E and V600D mutations, and in a xenograft model harboring a BRAF fusion. Molecular weight: 506.29 Formula: C17H12Cl2F3N7O2S CLOGP: 3.98 LIPINSKI: 1 HAC: 9 HDO: 3 TPSA: 135.78 ALOGS: ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
April 23, 2024	FDA	Day One Biopharmaceuticals, Inc.
April 20, 2026	EMA	Ipsen Pharma

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EC04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS B-Raf serine-threonine kinase (BRAF) inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000190118	Cytochrome P450 3A Inducers
FDA MoA	N0000194133	Type II RAF Kinase Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:68495	apoptosis inducer
CHEBI has role	CHEBI:75047	B-Raf inhibitor

Related Drugs by ATC class:

L01EC B-Raf serine-threonine kinase (BRAF) inhibitors 3 drugs

dabrafenibencorafenibvemurafenib

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Relapsed or refractory pediatric low-grade glioma	indication	74532006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG	OJEMDA	DAY ONE BIOPHARMS	N217700	April 23, 2024	RX	TABLET	ORAL	April 23, 2029	NEW CHEMICAL ENTITY
25MG/ML	OJEMDA	DAY ONE BIOPHARMS	N218033	April 23, 2024	RX	FOR SUSPENSION	ORAL	April 23, 2029	NEW CHEMICAL ENTITY
100MG	OJEMDA	DAY ONE BIOPHARMS	N217700	April 23, 2024	RX	TABLET	ORAL	April 23, 2031	TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION
25MG/ML	OJEMDA	DAY ONE BIOPHARMS	N218033	April 23, 2024	RX	FOR SUSPENSION	ORAL	April 23, 2031	TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
RAF proto-oncogene serine/threonine-protein kinase	Kinase	P04049	RAF1_HUMAN	INHIBITOR	IC50	9.15		DRUG LABEL	DRUG LABEL
Serine/threonine-protein kinase B-raf	Kinase	P15056	BRAF_HUMAN	INHIBITOR	IC50	8.08		DRUG LABEL	DRUG LABEL
Breakpoint cluster region protein	Kinase	P11274	BCR_HUMAN		Kd	6.53		CHEMBL
Ephrin type-A receptor 2	Kinase	P29317	EPHA2_HUMAN		Kd	6.09		CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	5.36		CHEMBL
LIM domain kinase 1	Kinase	P53667	LIMK1_HUMAN		Kd	5.99		CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	7		CHEMBL
Mitogen-activated protein kinase 11	Kinase	Q15759	MK11_HUMAN		Kd	6.17		CHEMBL
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		Kd	6.45		CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	6.76		CHEMBL
Dual specificity protein kinase CLK1	Kinase	P49759	CLK1_HUMAN		Kd	6.03		CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	7.20		CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN		Kd	4.95		CHEMBL
TGF-beta receptor type-2	Kinase	P37173	TGFR2_HUMAN		Kd	5.79		CHEMBL
Wee1-like protein kinase	Kinase	P30291	WEE1_HUMAN		Kd	6.60		CHEMBL
Mitogen-activated protein kinase kinase kinase MLT	Kinase	Q9NYL2	MLTK_HUMAN		Kd	6.35		CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	6.64		CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4	Kinase	P45985	MP2K4_HUMAN		Kd	6.84		CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN		Kd	5.97		CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Kinase	Q13627	DYR1A_HUMAN		Kd	5.49		CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	5.48		CHEMBL
Mitogen-activated protein kinase kinase kinase 1	Kinase	Q13233	M3K1_HUMAN		Kd	5.68		CHEMBL
Receptor-interacting serine/threonine-protein kinase 3	Kinase	Q9Y572	RIPK3_HUMAN		Kd	5.75		CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN		Kd	5.03		CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	6.30		CHEMBL

External reference:

ID	Source
QOP	PDB_CHEM_ID
CHEMBL3348923	ChEMBL_ID
C000626518	MESH_SUPPLEMENTAL_RECORD_UI
DB15266	DRUGBANK_ID
4043091	VANDF
C4287814	UMLSCUI
11985	INN_ID
25161177	PUBCHEM_CID
384705	MMSL
42790	MMSL
d10185	MMSL
019731	NDDF
9977	IUPHAR_LIGAND_ID
ZN90E4027M	UNII
2682434	RXNORM
D12291	KEGG_DRUG
CHEBI:167672	CHEBI
ZN90E4027M	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
OJEMDA	HUMAN PRESCRIPTION DRUG LABEL	1	82950-001	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections